Afficher la notice abrégée

Comparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases

hal.structure.identifierAix-Marseille Université - Faculté de médecine [AMU MED]
dc.contributor.authorDUROZARD, Pierre
hal.structure.identifierCentre de résonance magnétique biologique et médicale [CRMBM]
dc.contributor.authorRICO, Audrey
hal.structure.identifierCentre de résonance magnétique biologique et médicale [CRMBM]
dc.contributor.authorBOUTIÈRE, Clémence
hal.structure.identifierCentre de résonance magnétique biologique et médicale [CRMBM]
dc.contributor.authorMAAROUF, Adil
hal.structure.identifierPhysiopathologie de l'Endothelium
hal.structure.identifierCentre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research [C2VN]
hal.structure.identifierHôpital de la Conception [CHU - APHM] [LA CONCEPTION]
dc.contributor.authorLACROIX, Romaric
hal.structure.identifierVascular research center of Marseille [VRCM]
hal.structure.identifierCentre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research [C2VN]
hal.structure.identifierHôpital de la Conception [CHU - APHM] [LA CONCEPTION]
dc.contributor.authorCOINTE, Sylvie
hal.structure.identifierAix-Marseille Université - Faculté de pharmacie [AMU PHARM]
dc.contributor.authorFRITZ, Shirley
hal.structure.identifierHôpital de la Conception [CHU - APHM] [LA CONCEPTION]
dc.contributor.authorBRUNET, Corinne
hal.structure.identifierCentre de résonance magnétique biologique et médicale [CRMBM]
dc.contributor.authorPELLETIER, Jean
hal.structure.identifierHospices Civils de Lyon, Departement de Neurologie [HCL]
dc.contributor.authorMARIGNIER, Romain
hal.structure.identifierInstitut de Mécanique et d'Ingénierie de Bordeaux [I2M]
dc.contributor.authorAUDOIN, Bertrand
dc.date.accessioned2021-05-14T09:35:19Z
dc.date.available2021-05-14T09:35:19Z
dc.date.issued2019-12-10
dc.identifier.issn0364-5134
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/76201
dc.description.abstractEnObjective To compare response to rituximab (RTX) between adult patients positive for myelin oligodendrocyte glycoprotein (MOG) and aquaporin-4 (AQP4) antibodies. Methods We prospectively studied adult patients with MOG or AQP4 antibodies who received RTX under an individualized dosing schedule adapted to the biological effect of RTX monitored by memory B-cell measurement. Memory B cells were counted monthly and when relapse occurred. The biological effect of RTX was considered significant with <0.05% memory B cells in peripheral blood lymphocytes. Results In 16 patients with MOG antibodies and 29 with AQP4 antibodies, mean follow-up was 19 (range = 9-38) and 38 (13-79) months. Under RTX, 10 relapses occurred in 6 of 16 (37.5%) patients with MOG antibodies, and 13 occurred in 7 of 29 (24%) with AQP4 antibodies. The median time of relapse after the most recent infusion was 2.6 (0.6-5.8) and 7 (0.8-13) months, respectively (p < 0.001). Memory B cells had reemerged in 2 of 10 (20%) relapses in patients with MOG antibodies and 12 of 13 (92.5%) with AQP4 antibodies (p < 0.001). Interpretation In AQP4 antibody-associated disorder, relapse mostly occurs when the biological effect of RTX decreases, which argues for treatment efficacy. In MOG antibody-associated disorder, the efficacy of RTX is not constant, because one-third of patients showed relapse despite an effective biological effect of RTX. In this subpopulation, memory B-cell depletion was unable to prevent relapse, which was probably caused by different immunological mechanisms. These findings should be used to improve treatment strategies for MOG antibody-associated disorder. ANN NEUROL 2019
dc.language.isoen
dc.publisherWiley
dc.subject.enOPTICA SPECTRUM DISORDERS
dc.subject.enB-CELL DEPLETION
dc.subject.enNEUROMYELITIS-OPTICA
dc.subject.enLYMPHOID ORGANS
dc.subject.enHUMAN SPLEEN
dc.subject.enLONG
dc.subject.enEFFICACY
dc.subject.enTHERAPY
dc.subject.enINSIGHTS
dc.subject.enOUTCOMES
dc.title.enComparison of the Response to Rituximab between Myelin Oligodendrocyte Glycoprotein and Aquaporin‐4 Antibody Diseases
dc.typeArticle de revue
dc.identifier.doi10.1002/ana.25648
dc.subject.halSciences du Vivant [q-bio]
bordeaux.journalAnnals of Neurology
bordeaux.page256-266
bordeaux.volume87
bordeaux.hal.laboratoriesInstitut de Mécanique et d’Ingénierie de Bordeaux (I2M) - UMR 5295*
bordeaux.issue2
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.institutionINRAE
bordeaux.institutionArts et Métiers
bordeaux.peerReviewedoui
hal.identifierhal-02571419
hal.version1
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-02571419v1
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=Annals%20of%20Neurology&amp;rft.date=2019-12-10&amp;rft.volume=87&amp;rft.issue=2&amp;rft.spage=256-266&amp;rft.epage=256-266&amp;rft.eissn=0364-5134&amp;rft.issn=0364-5134&amp;rft.au=DUROZARD,%20Pierre&amp;RICO,%20Audrey&amp;BOUTI%C3%88RE,%20Cl%C3%A9mence&amp;MAAROUF,%20Adil&amp;LACROIX,%20Romaric&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée